Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

First Patient Dosed in the Phase I/II Study of UC1010 for PMDD Patients

Published: Monday, May 27, 2013
Last Updated: Monday, May 27, 2013
Bookmark and Share
First patient has been dosed with UC1010 in a double-blind, multicenter study.

Umecrine Mood AB has announced that dosing has been initiated in a randomized Phase I/II study of UC1010 for the treatment of patients with premenstrual dysphoric disorder (PMDD).

Umecrine Mood is part of the Karolinska Development portfolio.

Most women experience some form of symptoms the days before menstruation but in about five percent of young and middle-aged women, the symptoms are so severe that they are considered to be suffering from PMDD.

This means that the symptoms in a debilitating way affect daily life and relationships to other people.

"The symptoms occur due to that a breakdown product of a sex hormone affect the brain's emotional center. Umecrine Mood is the first company to successfully develop compounds that are proven to reduce the activity of the breakdown product in healthy individuals. Now we take the next step to evaluate the safety and efficacy of our drug candidate in patients", says Karin Ekberg, CEO of Umecrine Mood.

The first patient has now been dosed with UC1010 in a double-blind, multicenter study in which the safety and efficacy of the product will be evaluated in a total of 120 individuals.

Principal Investigator is Professor Marie Bixo, Institute of Clinical Research and Education, Södersjukhuset, Karolinska Institutet.

"The currently available treatment of PMDD is primarily antidepressant drugs, which are not always effective and often cause side effects", says Torbjörn Bjerke, CEO of Karolinska Development AB.

Bjerke continued, "There is no doubt that these women are in need of an effective and targeted treatment, nor that the health economic benefits of being able to help the patient group would be significant."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Dilafor Enters into a License and Partnership Agreement with Lee’s Pharmaceutical
Dilafor grants the right to manufacture, develop and commercialize tafoxiparin to Lee's Pharmaceutical.
Friday, February 21, 2014
Pergamum Announces Final Data from Phase I/II Study of LL-37
Phase I/II trial of LL-37 for treatment of patients with chronic leg ulcers.
Thursday, October 10, 2013
Lipidor Reports Positive Clinical Phase I/II Data in Psoriasis
Company is developing AKVANO®/calcipotriol for the treatment of psoriasis vulgaris.
Thursday, August 29, 2013
Pharmanest Meets All Efficacy and Safety End Points in Phase II Study of SHACT
Data show that SHACT is effective in reducing pain during IUD insertion.
Monday, August 05, 2013
Pergamum Reports Positive Data from Phase II Clinical Trial of PXL-01
Follow-up data from the Phase II clinical trial for prevention of post-surgical adhesions.
Thursday, June 27, 2013
Pharmanest Initiates Phase I Trial with SHACT
Trial is expected to enroll 15 patients and the study will be conducted at the Karolinska University Hospital.
Monday, October 15, 2012
Pergamum Reports Top Line Phase II-data from the Clinical Trial of PXL-01
The final Phase II report is expected to be published in the third quarter 2012.
Monday, August 06, 2012
Pharmanest Initiates Phase II Study of SHACT
Goal of the study is to evaluate the effect of SHACT in connection with IUD insertion in women.
Tuesday, June 19, 2012
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
Diagnostic Test Developed for Enterovirus D68
researchers at Washington University School of Medicine in St. Louis have developed a diagnostic test to quickly detect enterovirus D68 (EV-D68), a respiratory virus that caused unusually severe illness in children last year.
How a Kernel Got Naked and Corn Became King
Ten thousand years ago, a golden grain got naked, brought people together and grew to become one of the top agricultural commodities on the planet.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
New Material Opens Possibilities for Super-Long-Acting Pills
A pH-responsive polymer gel could create swallow able devices, including capsules for ultra-long drug delivery.
How To Keep Your Rice Arsenic-Free
Researchers at Queen’s University Belfast have made a breakthrough in discovering how to lower worrying levels of arsenic in rice that is eaten all over the world.
New Tool For Investigating RNA Gone Awry
A new technology – called “Sticky-flares” – developed by nanomedicine experts at Northwestern University offers the first real-time method to track and observe the dynamics of RNA distribution as it is transported inside living cells.
Computer Model Could Explain how Simple Molecules Took First Step Toward Life
Two Brookhaven researchers developed theoretical model to explain the origins of self-replicating molecules.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!